Posted by Michael Wonder on 12 Jun 2020
Orphan drug reimbursements create tough situation for South Korean public budget
12 June 2020 - A data analysis of real-world data found that the rise of orphan drugs in the Republic of Korea has not solved all patient accessibility issues as budget concerns can make it difficult to justify reimbursements.
Although orphan drug use in the Republic of Korea has risen, high drug prices and a low number of treated patients present challenges as the government looks to allocate the portion of its budget for reimbursement of such drugs, said investigators of a long-term real-world data analysis on the subject.
The Republic of Korea, which has a system of national health coverage, implemented a health technology assessment system in 2007.
